SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+32.69%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$324M
AUM Growth
+$324M
(+21%)
Cap. Flow
-$75.2M
Cap. Flow
% of AUM
-23.19%
Top 10 Holdings %
Top 10 Hldgs %
40.14%
Holding
88
New
16
Increased
27
Reduced
15
Closed
20
Top Buys
| 1 |
Nuvalent
NUVL
|
$14.2M |
| 2 |
Rocket Pharmaceuticals
RCKT
|
$11.5M |
| 3 |
Medtronic
MDT
|
$11.1M |
| 4 |
Sanofi
SNY
|
$10.9M |
| 5 |
Celldex Therapeutics
CLDX
|
$9.8M |
Top Sells
| 1 |
Praxis Precision Medicines
PRAX
|
$85.4M |
| 2 |
IMGN
Immunogen Inc
IMGN
|
$20.7M |
| 3 |
Soleno Therapeutics
SLNO
|
$11.9M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$9.22M |
| 5 |
CBAY
Cymabay Therapeutics
CBAY
|
$8.76M |
Sector Composition
| 1 | Healthcare | 99.98% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Merus
MRUS
$4.98B
| $17.8M | 5.28% | 645,581 +145,581 | +29% | +$4M |
|
2
Mersana Therapeutics
MRSN
$36.5M
| $14.9M | 4.43% | 6,420,136 +1,420,136 | +28% | +$3.29M |
|
|
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $14.4M | 4.3% | 500,042 -90,787 | -15% | -$2.62M |
|
|
4
Nuvalent
NUVL
$5.52B
| $14.2M | 4.23% | +193,000 | New | +$14.2M |
|
|
PSTX
5
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $12.5M | 3.71% | 3,705,779 +137,794 | +4% | +$463K |
|
6
MacroGenics
MGNX
$112M
| $12.1M | 3.6% | 1,258,641 -5,517 | -0.4% | -$53.1K |
|
|
7
Rocket Pharmaceuticals
RCKT
$354M
| $11.5M | 3.41% | +382,672 | New | +$11.5M |
|
|
8
Medtronic
MDT
$119B
| $11.1M | 3.31% | +135,000 | New | +$11.1M |
|
|
9
Sanofi
SNY
$121B
| $10.9M | 3.26% | +220,000 | New | +$10.9M |
|
10
Oric Pharmaceuticals
ORIC
$994M
| $10.8M | 3.2% | 1,170,000 +46,655 | +4% | +$429K |
|
|
11
Celldex Therapeutics
CLDX
$1.47B
| $9.8M | 2.92% | +247,215 | New | +$9.8M |
|
12
Olema Pharmaceuticals
OLMA
$375M
| $8.05M | 2.4% | 573,830 +166,029 | +41% | +$2.33M |
|
13
Rhythm Pharmaceuticals
RYTM
$6.85B
| $8.01M | 2.38% | 174,248 -86,289 | -33% | -$3.97M |
|
14
UroGen Pharma
URGN
$900M
| $7.88M | 2.35% | 525,404 +16,521 | +3% | +$248K |
|
15
Xenon Pharmaceuticals
XENE
$2.98B
| $7.52M | 2.24% | 163,168 +109,172 | +202% | +$5.03M |
|
16
Veracyte
VCYT
$2.39B
| $6.81M | 2.03% | 247,723 +8,152 | +3% | +$224K |
|
|
17
Praxis Precision Medicines
PRAX
$958M
| $6.32M | 1.88% | 283,841 -3,834,079 | -93% | -$85.4M |
|
18
Akero Therapeutics
AKRO
$3.74B
| $5.82M | 1.73% | 249,254 +217,918 | +695% | +$5.09M |
|
19
Pliant Therapeutics
PLRX
$101M
| $5.77M | 1.72% | 318,524 +68,115 | +27% | +$1.23M |
|
|
ITCI
20
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $5.73M | 1.71% | 80,000 -128,730 | -62% | -$9.22M |
|
21
Cogent Biosciences
COGT
$1.69B
| $5.68M | 1.69% | 966,748 +315,376 | +48% | +$1.85M |
|
|
ALPN
22
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $5.68M | 1.69% | +297,789 | New | +$5.68M |
|
23
Gossamer Bio
GOSS
$562M
| $5.59M | 1.67% | 6,130,268 | – | – |
|
24
Intuitive Surgical
ISRG
$170B
| $5.33M | 1.59% | +15,808 | New | +$5.33M |
|
25
TELA Bio
TELA
$70.5M
| $5.26M | 1.57% | 795,080 +304,609 | +62% | +$2.02M |
|